Senhwa Biosciences, a clinical-stage biopharmaceutical company based in Taiwan, has entered a partnership with a global investment group to accelerate its artificial intelligence-related drug development. According to an April 14 report, Senhwa Biosciences has signed a Memorandum of Understanding (MOU)…News, Adoption, AI, fundingRead More

You might also be interested in reading Former Paxful CEO Ray Youssef Urges Platform Users to ‘Cease Trading’.